Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.42 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22571431 | 0.84 | RXFP1 (0.48) | RXFP1ABCG2MAPK8PTGS1SMN1; SMN2 | |
| SCHEMBL25677942 | 0.82 | TGM2 (0.52) | TGM2RXFP1MAPK8TRPA1TRPM8 | |
| SCHEMBL22556306 | 0.82 | RXFP1 (0.53) | RXFP1ABCG2MAPK8PTGS1SMN1; SMN2 | |
| SCHEMBL22571408 | 0.81 | RXFP1 (0.50) | RXFP1ABCG2MAPK8PTGS1SMN1; SMN2 | |
| SCHEMBL29824749 | 0.80 | TGM2 (0.68) | TGM2RXFP1TRPA1TRPM8NPC1 | |
| SCHEMBL23591752 | 0.80 | TGM2 (0.68) | TGM2RXFP1TRPA1TRPM8NPC1 | |
| SCHEMBL22556341 | 0.80 | RXFP1 (0.51) | RXFP1ABCG2MAPK8PTGS1SMN1; SMN2 | |
| SCHEMBL22571350 | 0.80 | RXFP1 (0.51) | RXFP1ABCG2MAPK8PTGS1SMN1; SMN2 | |
| SCHEMBL22556311 | 0.80 | RXFP1 (0.48) | RXFP1ABCG2MAPK8PTGS1SMN1; SMN2 | |
| SCHEMBL25529311 | 0.80 | RXFP1 (0.48) | RXFP1ABCG2MAPK8PTGS1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | TGM2 1350/4885RXFP1 3511/4885ABCG2 2985/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | TGM2 1350/4885RXFP1 3511/4885ABCG2 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.